Viavi Solutions reports its latest quarterly results today against a striking backdrop: the stock has badly underperformed its closest peers over the past week, even as the optical networking sector roars higher.
The peer divergence is the sharpest signal heading into the print. While AAOI jumped nearly 50% on the week and LITE added 30%, Viavi managed just a 21% weekly gain before pulling back 3.5% on Wednesday to close at $38.90. That lag looks more pronounced against SILC (+22%) and CIEN (+17%), names with overlapping exposure to AI-driven optical demand. The sector is clearly in favour — the question the print will answer is whether Viavi is participating or falling behind.
Options positioning offers no strong directional read. The put/call ratio at 0.51 is marginally below its 20-day average of 0.53, fractionally on the call-heavy side but well within normal range. There is no unusual defensive hedging, and the borrow market tells a similar non-story: availability remains extremely loose at more than 4,000%, meaning there is an enormous pool of shares available relative to what is currently borrowed. Short interest, at 5.3% of the free float, has crept up about 1.2% on the week but remains well below mid-June levels when it ran near 6.4%. Cost to borrow is negligible at 0.40%. None of this points to elevated squeeze risk or aggressive short conviction — the positioning looks neutral rather than charged.
The analyst debate is the more interesting tension. The consensus mean target of $64.57 implies roughly 66% upside from current levels — a wide gap that reflects genuine disagreement about recovery timing. Susquehanna lifted its target to $66 in early July while maintaining a Positive rating; Rosenblatt carries a $70 Buy target from June. The bull case centres on 5G network buildout, AI data centre connectivity demand, and the anti-counterfeiting business. Bears point to the telecom capex cycle recovering more slowly than hoped and cooling OSP demand. UBS, notably, holds a Neutral view with a $60 target — supportive of the stock but skeptical about the pace of re-rating. Institutional flows add a bullish undertone: T. Rowe Price added more than 9 million shares in the most recent quarter, now holding nearly 8% of the company. BlackRock also added roughly 880,000 shares. Those are meaningful accumulation signals from large active and passive managers.
The insider picture is less encouraging. CEO Oleg Khaykin sold nearly 294,000 shares across May 6-8 at prices above $51, netting over $13 million. That selling — at a significant premium to today's price — may partly explain why the stock has given back ground since spring even as peers accelerated. The one prior earnings reaction on record showed a 21.5% single-day gain on April 30, suggesting the stock can move sharply on a positive surprise.
Today's print will test whether Viavi's results justify re-convergence with a peer group that has decisively re-rated higher — or whether the CEO's May selling was prescient about what lies ahead in the numbers.
See the live data behind this article on ORTEX.
Open VIAV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
